These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Maru Y; Tanaka N; Itami M; Hippo Y Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504 [TBL] [Abstract][Full Text] [Related]
25. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes. Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242 [TBL] [Abstract][Full Text] [Related]
26. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164 [TBL] [Abstract][Full Text] [Related]
27. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation. Ding H; Liu J; Zou R; Cheng P; Su Y J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375 [TBL] [Abstract][Full Text] [Related]
28. Human liver organoids for disease modeling of fibrolamellar carcinoma. Narayan NJC; Requena D; Lalazar G; Ramos-Espiritu L; Ng D; Levin S; Shebl B; Wang R; Hammond WJ; Saltsman JA; Gehart H; Torbenson MS; Clevers H; LaQuaglia MP; Simon SM Stem Cell Reports; 2022 Aug; 17(8):1874-1888. PubMed ID: 35803261 [TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. Neureiter D; Stintzing S; Kiesslich T; Ocker M World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307 [TBL] [Abstract][Full Text] [Related]
30. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107 [TBL] [Abstract][Full Text] [Related]
31. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. Chen MH; Yang WL; Lin KT; Liu CH; Liu YW; Huang KW; Chang PM; Lai JM; Hsu CN; Chao KM; Kao CY; Huang CY PLoS One; 2011; 6(11):e27186. PubMed ID: 22087264 [TBL] [Abstract][Full Text] [Related]
32. Mini-organs with big impact: Organoids in liver cancer studies. Khawar MB; Wang Y; Majeed A; Afzal A; Haneef K; Sun H Oncol Res; 2023; 31(5):677-688. PubMed ID: 37547759 [TBL] [Abstract][Full Text] [Related]
33. Human liver cancer organoids: Biological applications, current challenges, and prospects in hepatoma therapy. Chen L; Wei X; Gu D; Xu Y; Zhou H Cancer Lett; 2023 Feb; 555():216048. PubMed ID: 36603689 [TBL] [Abstract][Full Text] [Related]
34. Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma. Lim JH; Park K; Choi KH; Kim CW; Lee JH; Weicker R; Pan CH; Kim SM; Park KC Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887321 [TBL] [Abstract][Full Text] [Related]
35. Integrating Network Pharmacology and Experimental Models to Investigate the Efficacy of Coptidis and Scutellaria Containing Huanglian Jiedu Decoction on Hepatocellular Carcinoma. Huang J; Guo W; Cheung F; Tan HY; Wang N; Feng Y Am J Chin Med; 2020; 48(1):161-182. PubMed ID: 31964157 [TBL] [Abstract][Full Text] [Related]
36. The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. Zou H; Shao CX; Zhou QY; Zhu GQ; Shi KQ; Braddock M; Huang DS; Zheng MH Expert Rev Gastroenterol Hepatol; 2016; 10(3):331-40. PubMed ID: 26558504 [TBL] [Abstract][Full Text] [Related]
37. Liver organoids as a primary human model to study HBV-mediated Hepatocellular carcinoma. A review. Sharma S; Rawal P; Kaur S; Puria R Exp Cell Res; 2023 Jul; 428(1):113618. PubMed ID: 37142202 [TBL] [Abstract][Full Text] [Related]
38. Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment. Lim JTC; Kwang LG; Ho NCW; Toh CCM; Too NSH; Hooi L; Benoukraf T; Chow PK; Dan YY; Chow EK; Toh TB; Fong ELS Biomaterials; 2022 May; 284():121527. PubMed ID: 35483200 [TBL] [Abstract][Full Text] [Related]
39. Three-Dimensional Macroporous Sponge for the Culture of Hepatocellular Carcinoma Patient-Derived Xenograft Organoids. Toh TB; Liu Z; Yu H; Fong ELS SLAS Technol; 2021 Jun; 26(3):249-254. PubMed ID: 33775155 [TBL] [Abstract][Full Text] [Related]
40. Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC. Wei Y; Song Q; Zhang F; Yuan T Can J Gastroenterol Hepatol; 2021; 2021():5601678. PubMed ID: 34912753 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]